ThinkPatternGet the app
Story
BUSINESS · NOV 17, 2026

Sellas Life Sciences Shares Surge on Cancer Vaccine Success

Sellas Life Sciences Group shares rose 175% after a phase 3 trial showed its cancer vaccine reduced death risk by 41% for leukemia patients.

Sellas Life Sciences Group shares surged 175% to $20.54 on Tuesday following the success of a phase 3 clinical trial for its experimental cancer vaccine, galinpepimut-S (GPS). The REGAL study focused on 126 patients with acute myeloid leukaemia who were ineligible for stem-cell transplants.

Results from the study showed the vaccine reduced the risk of death by 41% compared to the best available treatment. Patients treated with the vaccine reached a median overall survival of 24 months, while the control group reached 14.7 months. The company reported that the vaccine was generally well tolerated and presented no new safety concerns.

Sellas Life Sciences Group now plans to meet with the Food and Drug Administration to discuss an accelerated regulatory filing strategy. The company intends to submit a biologics licence application in the first half of 2027.


Reported across 3 outlets
Actors
SELLAS Life Sciences Group, Inc.Food and Drug Administration

Keep reading in the app

The full story and every source, free in the app.